Ipamorelin Dosage: Timing, Frequency, Injection Technique

Ipamorelin Dosage Protocol: The Exact Schedule

Standard subcutaneous protocol: 200 to 300 mcg per injection, once daily pre-sleep on an empty stomach, five days on and two days off. Reconstitute with bacteriteriostatic water, inject into abdominal subcutaneous fat, and hold the dose steady for 8 to 12 weeks before reassessing with a qualified clinician.

This is an operator manual, not a primer. If you already understand what a growth hormone secretagogue is and you are here to build the actual schedule, injection technique, and stack timing, this is the page. For the receptor biology and selectivity data behind ipamorelin, see our guide on growth hormone secretagogues vs HGH.

The Standard 8 to 12 Week Cycle Structure

Community and compounding-pharmacy protocols for ipamorelin converge on a specific rhythm, not just a dose. The peptide's roughly two-hour plasma half-life and rapid GH pulse mean daily dosing is what most protocols actually run, but total exposure duration is where structure matters.

The 5-on/2-off pattern is not arbitrary. It mirrors how many compounding pharmacy protocols structure GH secretagogue administration to avoid continuous receptor occupancy while still delivering a consistent pulse pattern most nights of the week. Running continuously for months without a break is common in forum reports, but there is no published human trial testing a 12-week-plus continuous ipamorelin protocol for body composition or recovery outcomes, so treat any cycle beyond 12 weeks as unverified territory and check in with a qualified clinician before extending.

The CJC-1295 and Ipamorelin Stack Protocol

This is the most commonly run combination in the space, and it has a specific rationale that changes the injection schedule. CJC-1295 (without DAC, sometimes labeled Mod GRF 1-29) binds the GHRH receptor and tells the pituitary to produce GH. Ipamorelin binds the ghrelin receptor (GHS-R1a) and tells the pituitary to release it. Two separate signals converging on the same somatotroph cell.

The two peptides are typically drawn into separate syringes and injected within minutes of each other, same site or adjacent sites, because their half-lives are close enough (roughly 2 hours for ipamorelin, 30 minutes to 2 hours for CJC-1295 without DAC) that co-administration preserves the pulsatile pattern rather than flattening it into constant elevation. A 2006 human trial found that a single CJC-1295 injection produced dose-dependent increases in plasma GH of 2 to 10-fold sustained for 6 days or more, with IGF-1 elevated 1.5 to 3-fold for 9 to 11 days. Teichman et al. 2006 A follow-up study confirmed that continuous GHRH stimulation from CJC-1295 preserved the frequency and magnitude of GH pulses while raising the trough between them 7.5-fold. Ionescu and Frohman 2006 Neither trial combined CJC-1295 with ipamorelin directly, so the synergy rationale rests on mechanism, not a head-to-head human trial. For the complete build-out of this pairing, see our CJC-1295 and ipamorelin stack protocol, and if you are weighing CJC-1295's tolerability against running ipamorelin alone, our CJC-1295 side effects and safety guide covers that ground.

Subcutaneous Injection Technique, Step by Step

Ipamorelin is injected subcutaneously, not intramuscularly. The technique is straightforward but small errors (wrong needle depth, wrong injection site rotation) cause most of the reported bruising and site irritation.

1. Wash hands and clean the site. Alcohol swab the injection area and let it fully dry before proceeding.
2. Draw the dose. Use an insulin syringe (typically 29 to 31 gauge, 0.5 inch needle) to draw the calculated volume based on your reconstitution concentration.
3. Pinch a fold of skin. Abdominal fat 2 inches from the navel is the most common site. Pinch to lift subcutaneous tissue away from muscle.
4. Insert at 45 to 90 degrees. A 90-degree angle is standard for most abdominal fat depth; use 45 degrees if you are lean and injecting into a thinner fold.
5. Inject slowly and steadily. Push the plunger over 5 to 10 seconds. Fast injection increases site discomfort.
6. Withdraw and rotate. Do not inject the same exact spot two nights running. Rotate between left abdomen, right abdomen, and upper thigh.

Injection site rotation matters more with daily dosing than with less frequent protocols, since repeated trauma to the same subcutaneous pocket is what produces the small hardened lumps some users report.

Reconstitution Math You Need Before the First Injection

Ipamorelin ships as a lyophilized powder, typically in 2mg or 5mg vials. Reconstituting incorrectly is the single most common dosing error reported in the space, not the injection itself.

Once reconstituted, refrigerate at 2 to 8°C and use within 20 to 30 days. Reconstituted ipamorelin left at room temperature degrades faster and loses potency well before the powder form would. For the full walkthrough on diluent ratios, insulin syringe unit markings, and shelf-life across different peptides, our peptide reconstitution guide covers the general math in more depth.

Timing Windows: Why Fasted and Why Pre-Sleep

Two timing rules show up across nearly every protocol, and both are grounded in how the ghrelin receptor pathway actually behaves.

Fasted administration. Circulating glucose and insulin blunt GH secretagogue signaling at the pituitary. Injecting after a meal, particularly one high in carbohydrate or protein, measurably dampens the GH pulse. A 20 to 30 minute fasted window before and after injection is the standard recommendation, meaning no food for roughly 2 hours prior.

Pre-sleep timing. The body's largest endogenous GH pulse occurs during the first few hours of slow-wave sleep. Timing an ipamorelin injection 30 to 60 minutes before bed layers the exogenous pulse on top of, rather than in competition with, that natural nocturnal surge. Subcutaneous ipamorelin peaks in plasma GH at approximately 30 to 40 minutes post-injection and returns to baseline within 2 to 3 hours, a window that lines up cleanly with sleep onset. Johansen et al. 1998

Some protocols add a second injection immediately post-workout on training days, on the logic that resistance exercise independently stimulates GH release and stacking the two signals compounds the pulse. This is common practice, not something tested in a dedicated trial.

What the Underlying Evidence Actually Supports

Before running any protocol, it is worth being precise about what has and has not been demonstrated in controlled human research, because the dosing framework above is built substantially on preclinical and pharmacokinetic data, not large outcome trials.

Ipamorelin was characterized as the first selective growth hormone secretagogue in a landmark 1998 study: even at doses 200-fold above the ED50 for GH release, it did not produce ACTH or cortisol elevations meaningfully different from GHRH alone, distinguishing it from older GHRPs like GHRP-6. Raun et al. 1998 Human pharmacokinetic modeling found a terminal half-life of approximately 2 hours with dose-proportional GH stimulation and a peak GH response at roughly 40 minutes post-dose. Johansen et al. 1998 In rats, subcutaneous ipamorelin dosed three times daily for 15 days increased longitudinal bone growth rate in a dose-dependent fashion without altering IGF-1 or bone resorption markers. Johansen et al. 1999

The only randomized, placebo-controlled human trial of ipamorelin used intravenous dosing (0.03 mg/kg twice daily) in postoperative bowel resection patients, not subcutaneous dosing for body composition or recovery. It found ipamorelin well tolerated with no serious adverse events, but did not meet its primary efficacy endpoint. Beck et al. 2014 That gap, a single IV trial in a surgical population versus the daily subcutaneous protocols run in practice, is the honest limitation underlying every dosing table in this article. Treat the numbers above as a research-informed operating framework, not a clinically validated prescription.

Managing Side Effects Across a Cycle

Ipamorelin's selectivity profile means the side effect list is shorter than older GHRPs, but it is not zero. The most frequently reported issues during an active cycle:

Numbness, tingling, or persistent joint pain warrant stopping the protocol and speaking with a qualified clinician rather than waiting it out. These are not expected outcomes of a well-run protocol.

Common Dosing Mistakes

• Injecting after eating. This blunts the GH pulse the entire protocol is built around.
• Escalating too fast. Jumping straight to 300 mcg in week one removes your ability to isolate tolerance issues.
• Skipping the off-cycle window. Running continuously for months without a break has no supporting trial data at any duration.
• Mixing CJC-1295 with DAC into a nightly pulsatile stack. The DAC form's multi-day half-life is designed for infrequent dosing, not nightly co-injection with ipamorelin; that pairing flattens pulsatility rather than preserving it.
• Storing reconstituted peptide at room temperature. Refrigeration is not optional once bacteriostatic water is added.

When to Reassess or Stop the Protocol

At the 8 to 12 week mark, most protocols call for a structured check-in rather than an indefinite continuation. Bloodwork tracking IGF-1, fasting glucose, and HbA1c gives an objective read on whether the protocol is producing the intended signal without pushing metabolic markers in the wrong direction. If IGF-1 has not moved from baseline after 8 weeks at a consistent 200 to 300 mcg dose, escalating further is unlikely to help given the dose-response plateau documented in preclinical work, and the more useful move is reassessing the stack or the timing rather than the milligram amount.

Anecdotally, users report the clearest signal in recovery quality and sleep depth within the first 3 to 4 weeks, with body composition changes, if any, taking longer to show. This content is for educational purposes only. These compounds are intended for research use, and nothing here is medical advice. Work with a qualified clinician before starting, adjusting, or stacking any peptide protocol, and source only from vendors who provide third-party certificates of analysis. Our recommended sources page lists vendor-neutral options for researchers who want verified purity before running any of the protocols above.

If you are deciding between ipamorelin and an oral alternative for the same ghrelin receptor pathway, our ipamorelin vs MK-677 comparison breaks down the practical differences in half-life and administration burden. And if GHRH-pathway dosing specifically is what you are trying to nail down next, our tesamorelin dosage protocol runs the same operator-manual format for that compound.